These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 35570237)
1. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Koch MW; Mostert J; Repovic P; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G J Neurol; 2022 Oct; 269(10):5319-5327. PubMed ID: 35570237 [TBL] [Abstract][Full Text] [Related]
2. A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. Koch MW; Mostert JP; Uitdehaag B; Cutter G Mult Scler; 2021 Oct; 27(12):1864-1874. PubMed ID: 33464149 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679 [TBL] [Abstract][Full Text] [Related]
4. Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis. Koch MW; Repovic P; Mostert J; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G Eur J Neurol; 2023 Sep; 30(9):2761-2768. PubMed ID: 37306560 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. Koch MW; Mostert J; Uitdehaag B; Cutter G Mult Scler; 2020 Oct; 26(12):1540-1549. PubMed ID: 31517591 [TBL] [Abstract][Full Text] [Related]
6. An enrichment strategy for clinical trials in SPMS. Koch MW; Metz L; Cutter G Mult Scler; 2021 Oct; 27(12):1884-1893. PubMed ID: 33404355 [TBL] [Abstract][Full Text] [Related]
7. Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set. Koch MW; Cutter GR; Giovannoni G; Uitdehaag BMJ; Wolinsky JS; Davis MD; Steinerman JR; Knappertz V Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e358. PubMed ID: 28680915 [TBL] [Abstract][Full Text] [Related]
8. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945 [TBL] [Abstract][Full Text] [Related]
9. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Bosma LV; Kragt JJ; Brieva L; Khaleeli Z; Montalban X; Polman CH; Thompson AJ; Tintoré M; Uitdehaag BM Mult Scler; 2009 Jun; 15(6):715-20. PubMed ID: 19383646 [TBL] [Abstract][Full Text] [Related]
10. Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. Koch MW; Mostert J; Repovic P; Bowen JD; Strijbis E; Uitdehaag B; Cutter G J Neurol; 2022 Mar; 269(3):1663-1669. PubMed ID: 34392376 [TBL] [Abstract][Full Text] [Related]
11. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389 [TBL] [Abstract][Full Text] [Related]
12. Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. W Koch M; Mostert J; Repovic P; Bowen JD; Strijbis E; Uitdehaag B; Cutter G Mult Scler; 2022 Jul; 28(8):1286-1298. PubMed ID: 34965774 [TBL] [Abstract][Full Text] [Related]
13. The timed 25-foot walk in a large cohort of multiple sclerosis patients. Kalinowski A; Cutter G; Bozinov N; Hinman JA; Hittle M; Motl R; Odden M; Nelson LM Mult Scler; 2022 Feb; 28(2):289-299. PubMed ID: 34100297 [TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442 [TBL] [Abstract][Full Text] [Related]
18. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D; Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067 [TBL] [Abstract][Full Text] [Related]
19. Potential of Timed 25-Foot Walk Values in Predicting Maximum Walking Distance in Persons with Multiple Sclerosis. Alshamrani F; Berger W; Alnajashi H; Payne MWC; Morrow SA Int J MS Care; 2020; 22(5):215-218. PubMed ID: 33177957 [TBL] [Abstract][Full Text] [Related]
20. Biomarkers of disability worsening in inactive primary progressive multiple sclerosis. Baeva ME; Tottenham I; Koch M; Camara-Lemarroy C J Neuroimmunol; 2024 Feb; 387():578268. PubMed ID: 38157653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]